Bristol’s DTC Moratorium Will Affect Muraglitazar, Abatacept Launches

Muraglitazar and abatacept are likely to be the first Bristol-Myers Squibb products significantly affected by the company's recent moratorium on direct-to-consumer advertising during a drug's first 12 months on the market

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet